Allorion Therapeutic Inks Agreement With AstraZeneca For EGFR L858R Allosteric Inhibitor Program

(RTTNews) - Allorion Therapeutics, a US and China-based biotechnology company, on Tuesday entered into an exclusive option and global license agreement with British drug major AstraZeneca plc (AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R https://www.nasdaq.com/articles/allorion-therapeutic-inks-agreement-with-astrazeneca-for-egfr-l858r-allosteric-inhibitor